Clinical Trials Browser

Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT05797948 2023-04-04

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase NA Unknown

20 enrolled

Lymphoid

Recurrence, Lymphoma, B-Cell

NCT01861002 2021-06-09

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

Phase 1 Completed

15 enrolled 10 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01121757 2016-09-12

Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

Phase 2 Terminated

11 enrolled 12 charts

Lymphoid

Lymphoma, Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT00351975 2014-12-23

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

Phase 1 Completed

56 enrolled

LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Myeloproliferative Disorders, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

Clinical Trials

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases